RxDoctor Payments Data

James Rodio, MD

Psychiatry · Chardon, OHNPI 1275614513

Payments from drug & device makers

$4,370in general payments, 2019–2025

Across 235 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$670
  • Teva Pharmaceuticals USA, Inc.$638
  • AbbVie$607
  • Lundbeck LLC$414
  • Neurocrine Biosciences, Inc.$358
  • E.r. Squibb & Sons, L.L.C.$264
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$4,16795%
  • Education$2035%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,370 in reported general payments places this provider in the 85th percentile of 1,119 psychiatry providers in Ohio.

See all psychiatry providers in Ohio

Medicare billing

Part B allowed, 2024
$70,308
Medicare patients
91
Services billed
577

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine24$184,433
FanaptIloperidone34$141,266
Invega SustennaPaliperidone Palmitate38$80,976
RexultiBrexpiprazole40$59,008
VraylarCariprazine Hcl32$47,956
SaphrisAsenapine Maleate11$32,282
Abilify MaintenaAripiprazole11$32,024
VyvanseLisdexamfetamine Dimesylate62$31,251
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl184$27,339
Lurasidone Hcl46$21,340
SuboxoneBuprenorphine Hcl/Naloxone Hcl24$19,227
Aripiprazole165$15,238
TrintellixVortioxetine Hydrobromide30$14,932
Paliperidone ErPaliperidone38$14,296
ZubsolvBuprenorphine Hcl/Naloxone Hcl13$13,973

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$638$184,43324 claims
Vanda Pharmaceuticals Inc.Fanapt$215$141,26634 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$670$91,03251 claims
Johnson & JohnsonInvega Sustenna$113$80,97638 claims
AbbVieVraylar, Saphris$607$80,23743 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix$75$46,18392 claims
Indivior Inc.Suboxone$263$19,22724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,119 psychiatry providers in Ohio.

Other psychiatry in Chardon

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →